Headlines about Mead Johnson Nutrition (NYSE:MJN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mead Johnson Nutrition earned a news impact score of 0.10 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.5089269091665 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Mead Johnson Nutrition (NYSE MJN) traded down $0.01 during trading hours on Thursday, hitting $89.98. The company’s stock had a trading volume of 11,923,399 shares, compared to its average volume of 3,238,250. Mead Johnson Nutrition has a 12-month low of $69.25 and a 12-month high of $94.40. The company has a current ratio of 2.15, a quick ratio of 1.77 and a debt-to-equity ratio of -7.57.
About Mead Johnson Nutrition
Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, Latin America and North America/Europe. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.
Receive News & Ratings for Mead Johnson Nutrition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition and related companies with MarketBeat.com's FREE daily email newsletter.